2026年美国临床肿瘤学会泌尿生殖系统癌症研讨会（2026 ASCO GU）将于2月26日~28日在美国旧金山举行，旨在向全球肿瘤学者传递国际泌尿肿瘤领域的最新研究进展。近日，2026 ASCO GU大会官网公布了研究题目，本期肿瘤资讯特别整理了重磅口头报告（Oral）标题，以飨读者。
前列腺癌
摘要号：14
Title：Patient reported outcomes (PRO) and tolerability of capivasertib (Cap) plus abiraterone (ab) versus placebo (pbo) plus abi in patients (pts) withPTEN-deficient metastatic hormone-sensitive prostate cancer (mHSPC)： CAPItello-281.
标题：CAPItello-281研究：卡匹色替联合阿比特龙对比安慰剂联合阿比特龙在PTEN缺陷型转移性激素敏感性前列腺癌（mHSPC）患者中的患者报告结局和耐受性
讲者：Daniel J. George （Duke Cancer Institute）
摘要号：15
Tilte：Final overall survival results from the EORTC 1333/PEACE-3 trial： Enzalutamide with or without radium-223 in metastatic castration-resistant prostate cancer.
标题：EORTC 1333/PEACE-3试验的最终总生存结果：恩扎卢胺联合或不联合镭223治疗转移性去势抵抗性前列腺癌
讲者：Enrique Gallardo （Parc Tauli University Hospital）
摘要号：16
Tilte：Overall survival from the phase 2 trial of abiraterone, olaparib, or abiraterone + olaparib in first-line metastatic castration-resistant prostate cancer (mCRPC) with DNA repair defects (BRCA Away).
标题：针对伴DNA修复缺陷的转移性去势抵抗性前列腺癌(mCRPC)的2期试验（BRCA Away）：阿比特龙、奥拉帕利或阿比特龙+奥拉帕利一线治疗的总生存期分析
讲者：Maha H.A.Hussain（Robert H. Lurie Comprehensive Cancer Center, Northwestern University）
摘要号：17
Tilte：Preliminary phase 1 dose escalation results of VIR-5500 (AMX-500), a dual-masked PRO-XTEN T-cell engager, in metastatic castration resistant prostate cancer (mCRPC).
标题：VIR-5500 (AMX-500)是一种双靶点遮蔽型PRO-XTEN T细胞衔接器，用于治疗mCRPC的初步1期剂量递增结果
讲者：Johann S. De Bono （Royal Marsden Hospital）
摘要号：18
Tilte：Health-related quality of life, pain, and symptomatic skeletal events in the phase 3 PSMAddition study of [177Lu]Lu-PSMA-617 (177Lu-PSMA-617)combined with ADT and ARPI in patients with PSMA-positive mHSPC.
标题：PSMAddition 3期研究：评估177Lu-PSMA-617联合ADT和ARPI治疗PSMA阳性mHSPC患者中与健康相关的生活质量、疼痛和症状性骨骼事件
讲者：Michael J. Morris（Memorial Sloan Kettering Cancer Center）
摘要号：19
Tilte：First-in-human assessment of actinium-225-prostate-specific membrane antigen (25Ac- PSMA)-Trillium (BAY 3563254)in mCRPC： Dose-escalation results of the phase 1 PAnTHa study.
标题：在mCRPC中首次对225-锕-前列腺特异性膜抗原(25Ac-PSMA)-Trillium (BAY 3563254)进行人体评估：1期PAnTHa研究的剂量递增结果
讲者：Fred Saad（Urologic Oncology, University of Montreal Hospital Centre (CHUM)）
摘要号：305
Tilte：Hormone therapy use and duration with post-operative radiotherapy for recurrent prostate cancer：An individual patient data meta-analysis.
标题：复发性前列腺癌术后放疗联合激素治疗的使用及持续时间：个体患者数据荟萃分析
讲者：Amar Upadhyaya Kishan （University of California）
摘要号：306
Tilte：Fifteen-year survival analysis from the ASCENDE-RT randomized trial of external beam boost versus brachytherapy boost in localized prostate cancer.
标题：ASCENDE-RT随机试验中的局部前列腺癌患者进行外照射强化治疗对比近距离放射强化治疗的十五年生存率分析
讲者：Scott Tyldesley（BC Cancer Vancouver）
摘要号：LBA307
Tilte：Androgen deprivation therapy and radiotherapy with or without cabazitaxel in very-high risk localized prostate cancer： First results of the PEACE-2 randomized phase III trial.
标题：PEACE-2随机III期试验的初步结果：在极高危局限性前列腺癌中采用雄激素剥夺疗法联合放疗（联合或不联合卡巴他赛）治疗
讲者：Karim Fizazi（Centre Oscar Lambret, University of Paris Saclay）
摘要号：308
Tilte：External validation of a digital pathology-based multimodal artificial intelligence (MMA)-derived prognostic biomarker in the randomised phase II CHHiP trial.
标题：在随机II期CHHiP试验中对基于数字病理学的多模态人工智能衍生的预后生物标志物进行外部验证
讲者：Anna Clare Wilkins（The Institute of Cancer Research and Royal Marsden NHS Foundation Trust）
摘要号：309
Tilte：Genomic alterations and pathologic responses to neoadjuvant androgen receptor pathway inhibitor (ARP) doublets vs docetaxel triplets in the Genomic Umbrella Neoadjuvant study (GUNS).
标题：基因组伞式新辅助研究(GUNS)中，新辅助雄激素受体通路抑制剂(ARPI)双药对比多西他赛三药方案的基因组改变和病理缓解情况
讲者：待定 单位：待定
尿路上皮癌
摘要号：LBA630
Tilte：Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle invasive bladder cancer (MIBC) who are eligible for cisplatin： Randomized, open-label, phase3 KEYNOTE-B15 study.
标题：KEYNOTE-B15研究：一项随机、开放标签、3期，对符合顺铂治疗条件的肌层浸润性膀胱癌(MIBC)患者，进行新辅助和辅助维恩妥尤单抗帕博利珠单抗治疗
讲者：Matthew D. Galsky（Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai）
摘要号：LBA631
Tilte：RC48G001： A phase2 study of disitamab vedotin in HER2-expressing previously treated advanced UC.
标题：RC48G001：一项针对既往接受过治疗的HER2表达晚期尿路上皮癌患者，使用维迪西妥单抗治疗的II期研究
讲者：Thomas Powles（Barts Cancer Centre, Queen Mary University of London, Royal Free NHS Service Trust）
摘要号：LBA632
Tilte：Circulating tumor DNA (ctDNA) to guide response-adapted bladder preservation in muscle invasive bladder cancer (MIBC： Integrated analysis of the RETAlN trials.
标题：RETAlN试验的综合分析：循环肿瘤DNA(ctDNA)指导的MIBC的适应性膀胱保留
讲者：Pooja Ghatalia（Fox Chase Cancer Center）
摘要号：633
Tilte：Circulating tumor (ct)DNA- guided adjuvant atezolizumab (atezo) in muscle-invasive bladder cancer (MIBC)： Exploratory analysis of ctDNAdynamics in the IMvigor011 trial.
标题：循环肿瘤DNA指导的阿替利珠单抗辅助治疗MIBC：IMvigor011试验中ctDNA动态的探索性分析
讲者：Thomas Powles（Barts Cancer Centre, Queen Mary University of London, Royal Free NHS Service Trust）
摘要号：634
Tilte：KEYMAKER-U04 substudy 04B： Firs-line (1L) enfortumab vedotin (EV) plus pembrolizumab (pembro)-based immune checkpoint inhibitor (ICI) combinations for advanced urothelial cancer (UC).
标题：KEYMAKER-U04子研究04B：一线维恩妥尤单抗联合基于帕博利珠单抗的免疫检查点抑制剂治疗晚期尿路上皮癌
讲者：Avivit Peer（Institute of Oncology, Rambam Health Care Campus）
摘要号：635
Tilte：Gemcitabine intravesical system (Gem-iDRS)in combination with cetrelimab (CET) versus chemoradiotherapy (CRT) in muscle-invasive bladder cancer (MlBC)： SunRlSe-2 final results.
标题：SunRlSe-2最终结果：吉西他滨膀胱内系统（Gem-iDRS）联合cetrelimab对比放化疗治疗MlBC的疗效
讲者：Andrea Necchi（Comprehensive Cancer Center Vita-Salute San Rarfaele University）
摘要号：636
Tilte：Urinary tumor DNA (utDNA)and circulating tumor DNA (ctDNA) in patients (pts) with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D)in NIAGARA.
标题：NIAGARA研究：接受围手术期度伐利尤单抗治疗的MIBC患者的尿液肿瘤DNA (utDNA)和循环肿瘤DNA (ctDNA)分析
讲者：Michiel S Van Der Heijden（Netherlands Cancer lnstitute）
摘要号：638
Tilte：Pathological outcomes and disease-free surviva(DFS)in KEYNOTE-905： Neoadjuvant and adiuvant (neoad-adi) enfortumab vedotin (EV)pluspembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible.
标题：KEYNOTE-905中的病理学结局和无病生存期(DFS)：在不适合接受顺铂治疗的MIBC患者中，进行新辅助和辅助维恩妥尤单抗联合帕博利珠单抗治疗
讲者：待定 单位：待定
当日时间：4：15-4：20 PM
摘要号：LBA639
Tilte：Updated clinical results and associated biomarkers from an ongoing phase 1 study of FX-909, a first-in-class peroxisome proliferator-activated receptor gamma (PPARG) inhibitor, in patients (pts)with advanced urothelial carcinoma (adv UC).
标题：FX-909（一种首创的过氧化物酶体增殖激活受体γ(PPARG)抑制剂）在晚期尿路上皮癌(adv UC)患者中进行的1期研究的最新临床结果和相关生物标志物
讲者：Matthew D. Galsky（lcahn School of Medicine at Mount Sinai）
摘要号：737
Tilte：Phase 2 trial of pembrolizumab (P) with response-guided bladder-sparing in patients with muscle-invasive bladder cancer (MIBC HCRN GU 20-444).
标题：帕博利珠单抗治疗MIBC患者的2期试验，采用缓解情况指导的膀胱保留策略(HCRN GU 20-444)
讲者：Jonathan F Anker（Icahn School of Medicine at Mount Sinai）
肾癌和睾丸癌、阴茎癌
摘要号：416
Tilte：CYTOSHRiNk：A randomized phase I trial of cytoreductive stereotactic hypofractionated radiotherapy with ipilimumab/nivolumab for metastatic kidney cancer.
标题：CYTOSHRiNk：一项针对转移性肾癌的细胞减灭立体定向低分割放射治疗联合伊匹木单抗/纳武利尤单抗的随机I期试验
讲者：Aly-Khan A. Lalani（Juravinski Cancer Centre, McMaster University）
摘要号：LBA417
Tilte：Belzutifan (bel) plus lenvatinib (lenva) versus cabozantinib (cabo)for advanced renal cell carcinoma (RCC) after anti-PD-(L)1 therapy：Open-label phase 3 LITESPARK-011 study.
标题：贝组替凡联合仑伐替尼对比卡博替尼治疗抗PD-(L)1治疗后的晚期肾细胞癌(RCC)的疗效：开放标签3期 LITESPARK-011 研究
讲者：待定 单位：待定
摘要号：LBA418
Tilte：Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study.
标题：3期随机LITESPARK-022研究：帕博利珠单抗联合贝组替凡对比帕博利珠单抗单药治疗透明细胞肾细胞癌（ccRCC）的辅助治疗
讲者：Toni K. Choueiri（Dana-Farber Cancer Institute and Harvard Medical School）
摘要号：420
Tilte：Patient-reported outcomes in resected renal cell carcinoma： Active monitoring vs. durvalumab and tremelimumab in the RAMPART trial.
标题：肾细胞癌切除术后患者报告结局：RAMPART试验中主动监测对比度伐利尤单抗联合替西木单抗的比较
讲者：Sophie Merrick （Medical Research Council Clinical Trials Unit at University College London）
摘要号：421
Tilte：Ultra-sensitive whole-genome sequencing-based molecular residual disease detection in resectable renal cell carcinoma： Preliminary results from the MONSTAR-SCREEN-3 study.
标题：MONSTAR-SCREEN-3 研究的初步结果：基于超灵敏全基因组测序的可切除肾细胞癌分子残留病灶检测
讲者：Taigo Kato（The Univeristy of Osaka, Graduate School of Medicine）
摘要号：422
Tilte：Fruquintinibo plus serplulimab as first-line therapy in metastatic or unresectable non-clear cell renal cell carcinoma (nccRCC： Updated efficacy and safety data from a multicenter, single-arm, phase Il trial.
标题：呋喹替尼联合斯鲁利单抗作为转移性或不可切除的非透明细胞肾细胞癌(nccRCC)的一线治疗：来自多中心、单臂II期试验的最新疗效和安全性数据
讲者：黄吉炜(上海交通大学医学院附属仁济医院)
摘要号：423
Tilte：Ascending dose escalation of belzutifan plus palbociclib for previously treated advanced clear cell renal cell carcinoma (ccRCC), Phase 1/2 LITESPARK-024 study part 1.
标题：1/2期LITESPARK-024研究第1部分：贝组替凡联合哌柏西利治疗既往接受过治疗的晚期透明细胞肾细胞癌(ccRCC)的剂量递增研究
讲者：David F. McDermott（Beth lsrael Deaconess Medical Center）
摘要号：424
Tilte：Outcome of intermittent or continuous axitinib (ax>)in combination with avelumab (ave) for metastatic renal cell carcinoma (mRCC： Insights from the Tide-A and Javelin Renal 101 (JR101)trials.
标题：间歇性或持续性阿昔替尼联合阿维鲁单抗治疗转移性肾细胞癌（mRCC）的疗效：来自Tide-A和Javelin Renal 101（JR101）试验的启示
讲者：Roberto lacovelli（Universita Cattollca del Sacro Cuore）
摘要号：537
Tilte：Circulating KIM-1 and ctDNA as prognostic markers in oligometastatic clear cell renal cell carcinoma (CcRCC： The K-COMPAsS model.
标题：循环KIM-1和ctDNA作为寡转移性透明细胞肾细胞癌(CcRCC)的预后标志物：K-COMPAsS模型
讲者：Chad Tang（The University of Texas MD Anderson Cancer Center）
摘要号：586
Tilte：Initial results from CLIMATE, a prospective cohort study assessing the clinical utllty of miR-371a-3p (miR-371)as a marker of minimal residual disease (MRD)in clinical stage 1 testicular germ cell tumour (TGCT)： ANZUP1906.
标题：CLIMATE的初步结果：一项前瞻性队列研究，评估了miR-371a-3p (miR-371)作为临床1期睾丸生殖细胞肿瘤(TGCT)中微小残留病(MRD)标志物的临床应用价值：ANZUP1906
讲者：Ben Tran（Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, Universty of Melbourne）
摘要号：587
Tilte：A phase II trial of cabozantinib in relapsed refractory germ-cell tumors (GCT).
中文标题：卡博替尼治疗复发难治性生殖细胞肿瘤（GCT）的II期试验
讲者：Jennifer King（Trustees of Indiana University）
2026 ASCO GU官网
排版编辑：肿瘤资讯-CY
苏公网安备32059002004080号
